According to Fosun Pharmaceutical's announcement, in the first three quarters of 2026, it achieved operating income of 30.463 billion yuan, an increase of 3.64%; net profit attributable to shareholders of listed companies was 3.879 billion yuan, an increase of 15.18%; after deducting non-net profit of 2,667 billion yuan, a year-on-year decrease of 8.32%. The third quarter of 2026 achieved operating income of 10.021 billion yuan, an increase of 1.44% year on year; net profit attributable to shareholders of listed companies was 1,292 billion yuan, an increase of 15.49% year on year; after deducting non-net profit of 946 million yuan. The total R&D investment in the first three quarters was 5.247 billion yuan, up 31.24% year on year. Revenue from innovative drugs increased 15.54% year on year, accounting for 35.43% of pharmaceutical business revenue. During the reporting period, 2 innovative drugs were approved for marketing, 1 innovative drug marketing application was accepted, and 5 innovative drug clinical trial applications were approved.

According to Fosun Pharmaceutical's announcement, in the first three quarters of 2026, it achieved operating income of 30.463 billion yuan, an increase of 3.64%; net profit attributable to shareholders of listed companies was 3.879 billion yuan, an increase of 15.18%; after deducting non-net profit of 2,667 billion yuan, a year-on-year decrease of 8.32%. The third quarter of 2026 achieved operating income of 10.021 billion yuan, an increase of 1.44% year on year; net profit attributable to shareholders of listed companies was 1,292 billion yuan, an increase of 15.49% year on year; after deducting non-net profit of 946 million yuan. The total R&D investment in the first three quarters was 5.247 billion yuan, up 31.24% year on year. Revenue from innovative drugs increased 15.54% year on year, accounting for 35.43% of pharmaceutical business revenue. During the reporting period, 2 innovative drugs were approved for marketing, 1 innovative drug marketing application was accepted, and 5 innovative drug clinical trial applications were approved.